Full text is available at the source.
Exenatida diaria y semanal: perfil clínico de dos formulaciones pioneras en la modulación incretínica
Clinical features of two exenatide treatments given twice daily or once weekly for incretin therapy
AI simplified
Abstract
Weekly exenatide decreases HbA1c more than exenatide administered twice daily.
- Both exenatide formulations target the same receptors but have different effects on blood sugar levels.
- Exenatide administered twice daily shows a hypoglycemic effect comparable to other type 2 diabetes treatments and promotes significant weight loss with a low risk of causing low blood sugar.
- Weekly exenatide reduces HbA1c levels similarly to liraglutide and more than exenatide BID, glargine, biphasic insulin, sitagliptin, and pioglitazone.
- Weekly administration of exenatide maintains weight loss but is associated with gastrointestinal discomfort and injection site induration.
AI simplified